Enhancing adoptive T-cell therapy with fucoidan-based IL-2 delivery microcapsules

Eun Young Jeon, Da som Choi, Seunghyun Choi, Ju young Won, Yunju Jo, Hye bin Kim, Youngmee Jung, Sang Chul Shin, Hophil Min, Hae Woong Choi, Myeong Sup Lee, Yoon Park, Justin J. Chung, Hyung seung Jin

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)

Abstract

Adoptive cell therapy (ACT) with antigen-specific T cells is a promising treatment approach for solid cancers. Interleukin-2 (IL-2) has been utilized in boosting the efficacy of ACT. However, the clinical applications of IL-2 in combination with ACT is greatly limited by short exposure and high toxicities. Herein, a complex coacervate was designed to intratumorally deliver IL-2 in a sustained manner and protect against proteolysis. The complex coacervate consisted of fucoidan, a specific IL-2 binding glycosaminoglycan, and poly-l-lysine, a cationic counterpart (FPC2). IL-2-laden FPC2 exhibited a preferential bioactivity in ex vivo expansion of CD8+T cells over Treg cells. Additionally, FPC2 was embedded in pH modulating injectable gel (FPC2-IG) to endure the acidic tumor microenvironment. A single intratumoral administration of FPC2-IG-IL-2 increased expansion of tumor-infiltrating cytotoxic lymphocytes and reduced frequencies of myeloid populations. Notably, the activation and persistency of tumor-reactive T cells were observed only in the tumor site, not in the spleen, confirming a localized effect of FPC2-IG-IL-2. The immune-favorable tumor microenvironment induced by FPC2-IG-IL-2 enabled adoptively transferred TCR-engineered T cells to effectively eradicate tumors. FPC2-IG delivery system is a promising strategy for T-cell-based immunotherapies.

Original languageEnglish
Article numbere10362
JournalBioengineering and Translational Medicine
Volume8
Issue number1
DOIs
Publication statusPublished - 2023 Jan

Bibliographical note

Funding Information:
We thank the core facilities of Genetically Engineered Animal Core and flow cytometry at the ConveRgence mEDIcine research cenTer (CREDIT), Asan Medical Center. This study was supported by intramural grants of KIST, and National Research Foundation of Korea (NRF) grants (NRF-2021R1A2C2006647 to Yoon Park, NRF-2020R1C1C1012881 to Justin J. Chung, and NRF-2020R1A4A1016695 to Hyung-seung Jin) funded by the Korean government (MSIT).

Funding Information:
We thank the core facilities of Genetically Engineered Animal Core and flow cytometry at the ConveRgence mEDIcine research cenTer (CREDIT), Asan Medical Center. This study was supported by intramural grants of KIST, and National Research Foundation of Korea (NRF) grants (NRF‐2021R1A2C2006647 to Yoon Park, NRF‐2020R1C1C1012881 to Justin J. Chung, and NRF‐2020R1A4A1016695 to Hyung‐seung Jin) funded by the Korean government (MSIT).

Funding Information:
National Research Foundation of Korea, Grant/Award Numbers: NRF‐2020R1A4A1016695, NRF‐2020R1C1C1012881, NRF‐2021R1A2C2006647; KIST Funding information

Publisher Copyright:
© 2022 The Authors. Bioengineering & Translational Medicine published by Wiley Periodicals LLC on behalf of American Institute of Chemical Engineers.

Keywords

  • adoptive T-cell therapy
  • complex coacervate
  • fucoidan
  • immunotherapy
  • interleukin-2

ASJC Scopus subject areas

  • Biotechnology
  • Biomedical Engineering
  • Pharmaceutical Science

Fingerprint

Dive into the research topics of 'Enhancing adoptive T-cell therapy with fucoidan-based IL-2 delivery microcapsules'. Together they form a unique fingerprint.

Cite this